US and Europe (EU) Radiopharmaceutical Market (2026) | Growth, Trends, 5-Year Forecast & Key Players

DataM Intelligence has published a new research report on "US and Europe Radiopharmaceutical Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/us-and-europe-radiopharmaceutical-market?kb

United States: Recent Industry Developments
✅ February 2026: Cardinal Health expanded its radiopharmaceutical distribution network to improve supply chain efficiency for oncology diagnostics.
✅ January 2026: Curium USA partnered with leading hospitals to supply Lutetium-177 (Lu-177) therapies for targeted cancer treatment.
✅ December 2025: Pfizer initiated clinical trials for a new radiolabeled antibody therapy for neuroendocrine tumors.

Europe: Recent Industry Developments
✅ February 2026: Curium Europe launched advanced Tc-99m kits for cardiac imaging across EU hospitals.
✅ January 2026: GE Healthcare expanded production of PET tracers in Germany to meet rising oncology imaging demand.
✅ December 2025: Novartis secured EMA approval for a Lutetium-177 based radiopharmaceutical for prostate cancer therapy.

Latest M & A

• Ion Beam Applications S.A. acquired ORA, a Belgian radiochemistry firm, strengthening its radiopharmaceutical production and precision oncology capabilities (Dec 19, 2025) with consideration ~€15-20 M.

• Telix Pharmaceuticals Limited completed acquisition of RLS (USA) Inc., adding a network of ~30 Joint Commission-accredited radiopharmacies to enhance PET/SPECT/therapeutic radiopharmaceutical distribution in the U.S. (closed Jan 28, 2025).

Key Players:

Novartis (Advanced Accelerator Applications), Pfizer, Janssen Pharmaceuticals, Inc. (Johnson & Johnson, Inc.)

Key Development:

✅ February 2026: Leading radiopharmaceutical manufacturers in the US and Europe expanded production of novel PET and SPECT imaging tracers to meet rising demand in oncology and cardiology diagnostics.

✅ January 2026: Investment in automated synthesis modules and on-site cyclotrons increased to improve tracer yield, reduce production time, and enhance supply chain efficiency.

✅ December 2025: Hospitals and nuclear medicine centers adopted new theranostic agents for targeted cancer therapy, improving patient outcomes and supporting personalized medicine initiatives.

✅ November 2025: Regulatory approvals for next-generation radioisotopes accelerated in Europe and the US, facilitating wider clinical adoption and cross-border collaborations.

✅ October 2025: Companies integrated cold-chain logistics and digital tracking solutions to ensure radiopharmaceutical safety, compliance, and timely delivery across regional markets.

✅ August 2025: Partnerships between biotech firms and academic hospitals strengthened R&D efforts for alpha- and beta-emitting radiopharmaceuticals targeting rare cancers and cardiovascular conditions.

✅ June 2025: Growing demand for minimally invasive diagnostic imaging and government support for nuclear medicine research encouraged the adoption of cost-effective and high-precision radiopharmaceutical solutions across healthcare facilities.

Growth Forecast Projected:

The US and Europe Radiopharmaceutical Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the US and Europe Radiopharmaceutical Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=us-and-europe-radiopharmaceutical-market?kb

Key Segments:

By Product: Lutathera, Zytiga (Xtandi, Others)

By Indication: Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Prostate Cancer, Others

Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/us-and-europe-radiopharmaceutical-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Request For Custom Research: https://www.datamintelligence.com/custom-research?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.